Patients with coronary heart disease undergoing elective PCI
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria (1) Age and gender are not limited; (2) The diagnosis of coronary heart disease was in accordance with the relevant criteria of the "Guidelines for the Diagnosis and Treatment of stable coronary heart Disease", with chest tightness and chest pain, and aggravation after activity, confirmed by coronary angiography; 3 patients underwent percutaneous coronary intervention (PCI); Iv infusion (infusion of isotonic crystalloid solution) was prescribed; 5 had venous access; 6 Voluntarily participated in the trial and signed the "informed consent" voluntarily.
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1 Allergic to device materials and/or drugs to be infused; 2 patients with symptoms of phlebitis; 3. Plan to infuse fat-soluble liquid such as photosensitive, high viscosity, blood products and fat emulsion; 4 pregnant or lactating women; 5 patients with left main disease or severe multivessel disease; 6 patients underwent emergency PCI; 7 acute myocardial infarction; 8 Complicated with unstable angina pectoris, cardiac function class ?, cardiogenic shock, uncontrolled hypertension (resting systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg); 9 with arrhythmia (malignant ventricular arrhythmia, second or third degree atrioventricular block, supraventricular tachycardia, atrial fibrillation); 10 patients with renal insufficiency and stroke; 11 patients with intraoperative complications (acute heart failure, pericardial tamponade, acute coronary occlusion, coronary perforation, cardiogenic shock); Having any emergency medical condition requiring first aid; 13 participated in other clinical trials within 1 month before enrollment and/or participated in clinical trials that have not yet been completed; 14 mental inability or inability to understand the requirements for trial participation; 15 Other conditions considered by the investigator to be inappropriate for enrollment, such as coexisting medical conditions that limit participation in the trial, predicted poor adherence, and so on.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of pass; | — |
Secondary
| Measure | Time frame |
|---|---|
| Backflow resistance;no significant height difference in infusion function; | — |
Countries
China
Contacts
The Second affiliated Tangdu Hospital of Air Force Medical University